Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3071073 | Neurobiology of Disease | 2006 | 8 Pages |
Abstract
The transforming growth factor-betas (TGF-βs) regulate the induction of dopaminergic neurons and are elevated in the CSF of Parkinson's patients. We report here that mice with TGF-β2 haploinsufficiency (TGF-β2+/â) have subclinical defects in the dopaminergic neurons of their substantia nigra pars compacta. At 6 weeks of age, the TGF-β2+/â mice had 12% fewer dopaminergic neurons than wild-type littermates. No additional loss of neurons occurred during the next 5 months, although striatal dopamine declined to 70% of normal. The level of 3,4-dihydroxphenylacetic acid was normal in the TGF-β2+/â mice, indicating that a compensatory mechanism maintains dopamine stimulation of their striatum. The TGF-β2+/â mice had normal sensitivity to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tretrahydropyridine, despite having reduced levels of monoamine oxidase-B. These results raise the possibility that people with naturally low levels of TGF-β2 may have less functional reserve in their nigrostriatal pathway, causing them to be at increased risk of developing Parkinson disease.
Keywords
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Zane B. Andrews, Hua Zhao, Tony Frugier, Reiko Meguro, David R. Grattan, Kyoko Koishi, Ian S. McLennan,